262 related articles for article (PubMed ID: 27590257)
1. Vascular actions of relaxin: nitric oxide and beyond.
Leo CH; Jelinic M; Ng HH; Marshall SA; Novak J; Tare M; Conrad KP; Parry LJ
Br J Pharmacol; 2017 May; 174(10):1002-1014. PubMed ID: 27590257
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the understanding of relaxin family peptides and their receptors.
Summers RJ
Br J Pharmacol; 2017 May; 174(10):915-920. PubMed ID: 28447360
[TBL] [Abstract][Full Text] [Related]
3. Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.
Ferlin A; De Toni L; Sandri M; Foresta C
Br J Pharmacol; 2017 May; 174(10):1015-1024. PubMed ID: 27059798
[TBL] [Abstract][Full Text] [Related]
4. Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.
Ma S; Smith CM; Blasiak A; Gundlach AL
Br J Pharmacol; 2017 May; 174(10):1034-1048. PubMed ID: 27774604
[TBL] [Abstract][Full Text] [Related]
5. Relaxin family peptides: structure-activity relationship studies.
Patil NA; Rosengren KJ; Separovic F; Wade JD; Bathgate RAD; Hossain MA
Br J Pharmacol; 2017 May; 174(10):950-961. PubMed ID: 27922185
[TBL] [Abstract][Full Text] [Related]
6. Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells.
Klonisch T; Glogowska A; Thanasupawat T; Burg M; Krcek J; Pitz M; Jaggupilli A; Chelikani P; Wong GW; Hombach-Klonisch S
Br J Pharmacol; 2017 May; 174(10):1025-1033. PubMed ID: 27443788
[TBL] [Abstract][Full Text] [Related]
7. The actions of relaxin on the human cardiovascular system.
Sarwar M; Du XJ; Dschietzig TB; Summers RJ
Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943
[TBL] [Abstract][Full Text] [Related]
8. Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1.
Agoulnik AI; Agoulnik IU; Hu X; Marugan J
Br J Pharmacol; 2017 May; 174(10):977-989. PubMed ID: 27771940
[TBL] [Abstract][Full Text] [Related]
9. Impaired vascular responses to relaxin in diet-induced overweight female rats.
van Drongelen J; van Koppen A; Pertijs J; Gooi JH; Parry LJ; Sweep FC; Lotgering FK; Smits P; Spaanderman ME
J Appl Physiol (1985); 2012 Mar; 112(6):962-9. PubMed ID: 22174401
[TBL] [Abstract][Full Text] [Related]
10. Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice.
Marshall SA; Leo CH; Senadheera SN; Girling JE; Tare M; Parry LJ
Am J Physiol Regul Integr Comp Physiol; 2016 May; 310(9):R847-57. PubMed ID: 26936785
[TBL] [Abstract][Full Text] [Related]
11. Relaxin-like peptides in male reproduction - a human perspective.
Ivell R; Agoulnik AI; Anand-Ivell R
Br J Pharmacol; 2017 May; 174(10):990-1001. PubMed ID: 27933606
[TBL] [Abstract][Full Text] [Related]
12. Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.
Kumar JR; Rajkumar R; Jayakody T; Marwari S; Hong JM; Ma S; Gundlach AL; Lai MKP; Dawe GS
Br J Pharmacol; 2017 May; 174(10):1061-1076. PubMed ID: 27597467
[TBL] [Abstract][Full Text] [Related]
13. Anti-fibrotic actions of relaxin.
Samuel CS; Royce SG; Hewitson TD; Denton KM; Cooney TE; Bennett RG
Br J Pharmacol; 2017 May; 174(10):962-976. PubMed ID: 27250825
[TBL] [Abstract][Full Text] [Related]
14. Serelaxin in clinical development: past, present and future.
Unemori E
Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
[TBL] [Abstract][Full Text] [Related]
15. G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.
Conrad KP
Hum Reprod Update; 2016 Sep; 22(5):647-64. PubMed ID: 27385360
[TBL] [Abstract][Full Text] [Related]
16. From pregnancy to cardiovascular disease: Lessons from relaxin-deficient animals to understand relaxin actions in the vascular system.
Jelinic M; Marshall SA; Leo CH; Parry LJ; Tare M
Microcirculation; 2019 Feb; 26(2):e12464. PubMed ID: 29876993
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system.
Cirino G; Vellecco V; Bucci M
Br J Pharmacol; 2017 Nov; 174(22):4021-4031. PubMed ID: 28407204
[TBL] [Abstract][Full Text] [Related]
18. Sex-specific effects of relaxin-3 on food intake and body weight gain.
Calvez J; de Ávila C; Timofeeva E
Br J Pharmacol; 2017 May; 174(10):1049-1060. PubMed ID: 27245781
[TBL] [Abstract][Full Text] [Related]
19. Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice.
Ng HH; Jelinic M; Parry LJ; Leo CH
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H285-96. PubMed ID: 25957220
[TBL] [Abstract][Full Text] [Related]
20. The vascular actions of relaxin.
Jeyabalan A; Shroff SG; Novak J; Conrad KP
Adv Exp Med Biol; 2007; 612():65-87. PubMed ID: 18161482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
